Observational Study - TA- 2025-1
Launched by HAAG-STREIT AG · Jun 3, 2025
Trial Information
Current as of July 24, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • diagnosed with cataracts (any grade),
- • Seeking cataract treatment,
- • willing to provide informed consent.
- Exclusion Criteria:
- • Active ocular infections or trauma.
- • Poor fixation ability (e.g., severe nystagmus).
- • Prior intraocular surgery.
- • Seeking toric IOL implantation requiring ink marking.
About Haag Streit Ag
Haag-Streit AG is a globally recognized leader in the development and manufacturing of innovative diagnostic and surgical equipment for the ophthalmic and optometric fields. With a rich history of over 150 years, the company is committed to enhancing patient care through cutting-edge technology and high-quality products. Haag-Streit AG's extensive portfolio includes advanced imaging systems, precision instruments, and robust software solutions, all designed to support healthcare professionals in delivering accurate diagnoses and effective treatments. The organization is dedicated to advancing clinical research and improving visual health outcomes worldwide, making significant contributions to the field of eye care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mesa, Arizona, United States
Eugene, Oregon, United States
Patients applied
Trial Officials
Jan Rübel, PhD
Study Chair
Haag-Streit
Julian V Kool van Langenberghe, ing
Study Director
Haag-Streit
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported